BioStar Capital closes Fund V with $130m

BioStar Capital, a prominent strategic venture capital firm specializing in groundbreaking medical technologies within cardiovascular disease, orthopedics, and robotics, recently announced the successful closure of its fifth fund, totaling $130.3 million. This achievement surpasses the combined capitalization of its three preceding funds.

Headed by founder Louis Cannon, M.D., a distinguished cardiovascular physician, innovator, and educator, alongside Alan Davis, M.D., an orthopedic surgeon and Emeritus Staff at The Cleveland Clinic, BioStar Capital's Fund V has curated a portfolio featuring cutting-edge medical device companies. The firm, renowned for its commitment to fostering transformative medical technologies, leverages the expertise of its team comprising esteemed healthcare clinicians, executives, thought leaders, and financial professionals to gain unique insights into each investment opportunity. This successful fundraise positions BioStar Capital as a key player in driving innovation within the medical technology sector.